Biotricity Delivers Strong Q3 Fiscal 2026 Performance

Growing Revenue Momentum and Expanding EBITDA

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Biotricity Inc., an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management, announced its financial results for the third quarter of fiscal 2026, ended December 31, 2025. The company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.

Why it matters

The need for proactive chronic care management has never been greater, with cardiovascular disease projected to impact over 60% of the population and cost nearly $1.8 trillion over the next 30 years. Biotricity is helping lead the transition to proactive monitoring by bringing clinical-grade, easy-to-use diagnostic solutions out of episodic care settings and into everyday life.

The details

Biotricity reported a 10.2% increase in revenue to $4 million, with gross margin expanding to 81.5% due to growth in recurring technology fee revenue, efficiencies from proprietary AI in operational automation, and improvements in monitoring and cloud cost structure. The company also maintained a strong customer retention rate of over 90% and continued to expand its footprint across national markets.

  • Biotricity reported financial results for the third quarter of fiscal 2026, ended December 31, 2025.
  • The company is on track to obtain FDA clearance for its groundbreaking AI clinical model in the coming months.

The players

Biotricity Inc.

An innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions.

Dr. Waqaas Al-Siddiq

Biotricity Founder & CEO.

Got photos? Submit your photos here. ›

What they’re saying

“The need for proactive chronic care management has never been greater. We're proud to deliver our third consecutive quarter of positive EBITDA and net operating income, which reflects continued revenue growth, sustained margins, and disciplined operational execution.”

— Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO (Biotricity Press Release)

What’s next

The company is on track to obtain FDA clearance for its groundbreaking AI clinical model in the coming months.

The takeaway

Biotricity's strong financial performance, growing customer base, and innovative remote patient monitoring solutions position the company to lead the transition to proactive chronic care management and revolutionize the cardiac care landscape.